GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Retractable Technologies Inc (AMEX:RVP) » Definitions » Debt-to-EBITDA

Retractable Technologies (Retractable Technologies) Debt-to-EBITDA : 0.23 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Retractable Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Retractable Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.30 Mil. Retractable Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.23 Mil. Retractable Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $6.77 Mil. Retractable Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Retractable Technologies's Debt-to-EBITDA or its related term are showing as below:

RVP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.54   Med: -0.59   Max: 0.68
Current: -1.24

During the past 13 years, the highest Debt-to-EBITDA Ratio of Retractable Technologies was 0.68. The lowest was -10.54. And the median was -0.59.

RVP's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs RVP: -1.24

Retractable Technologies Debt-to-EBITDA Historical Data

The historical data trend for Retractable Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Retractable Technologies Debt-to-EBITDA Chart

Retractable Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.14 0.03 0.18 -1.24

Retractable Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 0.14 -0.15 -0.12 0.23

Competitive Comparison of Retractable Technologies's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Retractable Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Retractable Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Retractable Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Retractable Technologies's Debt-to-EBITDA falls into.



Retractable Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Retractable Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.304 + 1.234) / -1.237
=-1.24

Retractable Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.304 + 1.234) / 6.768
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Retractable Technologies  (AMEX:RVP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Retractable Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Retractable Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Retractable Technologies (Retractable Technologies) Business Description

Traded in Other Exchanges
N/A
Address
511 Lobo Lane, Little Elm, TX, USA, 75068-5295
Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The company's products are the VanishPoint 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the allergy tray; the IV safety catheter; the Patient Safe syringes; the Patient Safe Luer Cap; the VanishPoint Blood Collection Set; and the EasyPoint needle, as well as a standard 3mL syringe packaged with an EasyPoint needle. The company also sells VanishPoint autodisable syringes in the international market in addition to its other products.
Executives
Thomas J Shaw director, 10 percent owner, officer: President and CEO 511 LOBO LANE, LITTLE ELM TX 75068
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Bigby Walter O Jr director 816 BENTON RD, BOSSIER CITY LA 71111
Darren E Findley director 1618 GRASSMERE RD, FRANKLIN TN 37064
Russell B Kuhlman director, officer: Vice President of Sales 511 LOBO LANE, PO BOX 9, LITTLE ELM TX 75068
Fort John W Iii director, officer: Chief Financial Officer 511 LOBO LANE, LITTLE ELM TX 75068
Amy Mack director 1701 LEGACY DRIVE SUITE 100, FRISCO TX 75034
Clarence D Zierhut director 1217 BLUEBIRD LANE, GARLAND TX 75042
Lillian E Salerno 10 percent owner 777 7TH AVENUE, UNIT 308, WASHINGTON DC 20001
Suzanne M August 10 percent owner 340 NORTH JULIA CIRCLE, ST. PETERSBURG FL 33706
Steven R Wisner director, officer: Exec. VP, Eng & Prod. 511 LOBO LANE, PO BOX 9, LITTLE ELM TX 75068
Marco Laterza director P.O. BOX 64104, EL PASO TX 79904
Jimmie Shiu director 511 LOBO LANE, P.O. BOX 9, LITTLE ELM TX 75068
Patti King director 9145 MARTIN ROAD, ROSWELL GA 30076
Michele Larios officer: Vice President/General Counsel 511 LOBO LANE, LITTLE ELM TX 75068

Retractable Technologies (Retractable Technologies) Headlines